文献速递前列腺癌

活检前磁共振阴性者临床显著前列腺癌的基线及长期随访风险

Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
PubMed 文献 · J Urol · 2020-10-20

该研究纳入503例活检前磁共振阴性(PI-RADS 1-2)且未活检过的连续患者,基线行12针系统活检。基线临床显著前列腺癌(csPCa-1)为9%,长期随访总体发生率13%。PSA密度≥0.15 ng/ml/ml、临床分期≥T2a和前列腺癌家族史是csPCa的预测因素。

要点

  • 磁共振阴性且未活检人群中,基线csPCa风险为6%-9%,长期随访为7%-13%。
  • PSA密度≥0.15 ng/ml/ml、临床分期≥T2a和家族史是csPCa预测因素。
  • 对PSA密度≥0.15或DRE异常或家族史者活检,可减少漏诊并避免56%活检。

核心结论

  • 磁共振阴性且未活检人群中临床显著前列腺癌风险基线为6%-9%,长期随访为7%-13%,取决于定义。

研究设计与样本

  • 研究纳入2007至2017年连续503例活检前磁共振阴性(PI-RADS 1-2)且未活检过的患者,基线均行12针系统活检。
  • 随访中若直肠指检可疑或PSA动力学异常则行磁共振和活检,中位随访4年(IQR 1.6-7.1)。

主要发现

  • 基线活检显示csPCa-1为9%(45例),csPCa-2为6%(29例),非csPCa为22%(111例)。
  • 中位随访4年,415例未治疗患者中31%(95%CI 27-36)行第二次磁共振,24%(95%CI 20-28)行第二次活检,检出csPCa-1为5%(21/415,95%CI 3-7),csPCa-2为2%(7/415,95%CI 1-3)。
  • 总体发生率:csPCa-1为13%(66/503,95%CI 7-21),csPCa-2为7%(36/503,95%CI 5-9),高危前列腺癌为2%(12/503,95%CI 1.1-3.7)。
  • csPCa预测因素:PSA密度≥0.15 ng/ml/ml(OR 2.43,95%CI 1.19-4.21)、临床分期≥T2a(OR 3.32,95%CI 1.69-6.53)、前列腺癌家族史(OR 2.38,95%CI 1.10-6.16)。

关键数值与推荐

  • 临床显著前列腺癌-1(csPCa-1)定义为Gleason分级1且癌核心长度>5 mm,或≥3针阳性系统12针活检且Gleason分级≥2。
  • 临床显著前列腺癌-2(csPCa-2)定义为任何Gleason分级≥2。
  • 非临床显著前列腺癌-1定义为Gleason分级1且癌核心长度≤5 mm且<3针阳性;非临床显著前列腺癌-2定义为任何Gleason分级1。
  • 高危临床显著前列腺癌定义为Gleason分级≥3。

临床怎么用

  • 对磁共振阴性且PSA密度≥0.15 ng/ml/ml或直肠指检异常或前列腺癌家族史的患者行活检,可使基线漏诊csPCa-1风险从9%降至2.4%,同时避免56%的活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate biopsy should be discussed with the patient in cases of negative magnetic resonance imaging and low clinical suspicion of prostate cancer.Our primary objective was to describe the risk of clinically significant prostate cancer in a negative magnetic resonance imaging biopsy naïve population at baseline and during long-term followup. The secondary objective was to evaluate clinical factors and prostate specific antigen as predictors of clinically significant prostate cancer at baseline. MATERIALS AND METHODS: All 503 consecutive patients who were biopsy naïve referred from 2007 to 2017 for biopsy with negative magnetic resonance imaging (PI-RADS™ 1-2) who had systematic 12-core biopsies at baseline were included. Clinical factors were digital rectal examination, prostate cancer family history and prostate specific antigen. In case of suspicious digital rectal examination or prostate specific antigen kinetics during followup, magnetic resonance imaging and biopsy were performed. Clinically significant prostate cancer was defined as either Gleason Grade 1 with cancer core length greater than 5 mm or 3 or more positive systematic 12-core biopsies in addition to Gleason Grade 2 or greater (clinically significant prostate cancer-1) or any Gleason Grade 2 or greater (clinically significant prostate cancer-2). Nonclinically significant prostate cancer was defined as either Gleason Grade 1 with cancer core length 5 mm or less and fewer than 3 positive systematic 12-core biopsies (nonclinically significant prostate cancer-1) or any Gleason Grade 1 (nonclinically significant prostate cancer-2). Definition of high risk clinically significant prostate cancer was Gleason Grade 3 or greater. Univariate and multivariate models were fitted to identify predictors of clinically significant prostate cancer risk. RESULTS: At baseline, biopsy showed clinically significant prostate cancer-1 in 9% (45), clinically significant prostate cancer-2 in 6% (29) and nonclinically significant prostate cancer in 22% (111). At median followup of 4 years (IQR 1.6-7.1), 31% (95% CI 27-36) of 415 untreated patients had a second magnetic resonance imaging and 24% (95% CI 20-28) a second biopsy that showed clinically significant prostate cancer-1 in 5% (21/415, 95% CI 3-7), clinically significant prostate cancer-2 in 2% (7/415, 95% CI 1-3) and nonclinically significant prostate cancer in 8%. Overall incidence was 13% (66/503, 95% CI 7-21) for clinically significant prostate cancer-1, 7% (36/503, 95% CI 5-9%) for clinically significant prostate cancer-2 and 2% (12/503, 95% CI 1.1-3.7) for high risk prostate cancer. Predictors of clinically significant prostate cancer risk were prostate specific antigen density 0.15 ng/ml/ml or greater (OR 2.43, 1.19-4.21), clinical stage T2a or greater (OR 3.32, 1.69-6.53) and prostate cancer family history (OR 2.38, 1.10-6.16). Performing biopsy in patients with negative magnetic resonance imaging and prostate specific antigen density 0.15 ng/ml/ml or greater or abnormal digital rectal examination or prostate cancer family history would have decreased from 9% to 2.4% the risk of missing clinically significant prostate cancer-1 at baseline while avoiding biopsy in 56% of cases. CONCLUSIONS: The risk of clinically significant prostate cancer in a negative magnetic resonance imaging biopsy naïve population was 6% to 9% at baseline and 7% to 13% at long-term followup depending on clinically significant prostate cancer definitions.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Buisset J, Norris JM, Puech P, et al. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results. J Urol. 2020. PMID: 33080153. doi:10.1097/JU.0000000000001414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。